Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COVID-19: Pandemic Could Bring Advances In Diagnostics Development, Experts Say

Executive Summary

The diagnostics industry could benefit from a greater focus on real-world evidence linked to the COVID-19 pandemic, according to experts from the US FDA and industry.

You may also be interested in...



NESTcc Updates On Projects, Prepares For Winter Launch

An initial version of real-world data project NESTcc – the National Evaluation System for health Technology Coordinating Center – is expected to be open for business and ready to take unsolicited proposals by the end of the year.

Merit Medical To Pay $18M To Settle Kickback Case

The US Department of Justice says the company provided advertising assistance and educational grants to health care providers that used its embolization devices.

Priority Lane: Guidances On Risky Devices, 510(k) Reform Top FDA’s To-Do List

The US FDA hopes to finalize or issue draft guidance documents on about 30 topics in fiscal year 2021.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel